How to manage difficult Crohn’s disease: optimum delivery of anti-TNFs

References

• Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease (8th Edition). Elsevier, MO, USA, 2459 (2008).
   Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology121(2), 255–260 (2001).
   PubMed Web of Science ®Google Scholar
• Candy S, Wright J, Gerber M et al. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut37(5), 674–678 (1995).
   PubMed Web of Science ®Google Scholar
• Present DH, Korelitz BI, Wisch N et al. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N. Engl. J. Med.302(18), 981–987 (1980).
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Kohn N et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology119(4), 895–902 (2000).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN; The North American Crohn’s Study Group Investigators. Methotrexate for the treatment of Crohn’s disease. N. Engl. J. Med.332(5), 292–297 (1995).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. N. Engl. J. Med.342(22), 1627–1632 (2000).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Hampe J et al. Tumour necrosis factor α and interleukin 1β in relapse of Crohn’s disease. Lancet353(9151), 459–461 (1999).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol.6(6), 644–653 (2008).
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Moore MA, Trinh H et al. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine7(3), 251–259 (1995).
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJH et al. A short term study of chimeric monoclonal antibody cA2 to tumour necrosis factor for Crohn’s disease. N. Engl. J. Med.337, 1029–1036 (1997).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al.; ACCENT I study group. maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340(18), 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med.350(9), 876–885 (2004).
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Patel K et al. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin. Gastroenterol. Hepatol.2(10), 912–920 (2004).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology30(2), 323–333 (2006).
   Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s Disease: the CHARM trial. Gastroenterology132, 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med.357(3), 228–238 (2007).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Eng. J. Med.357(3), 239–250 (2007).
   PubMed Web of Science ®Google Scholar
• Vermeire S, Abreu MT, D’Haens G et al. Efficacy and safety of certolizumab pegol in patients with active Crohn’s disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the WELCOME study. Gastroenterology134(4), A-67 (2008) (Abstract 494).
   Google Scholar
• Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology126(6), 1593–1610 (2004).
   PubMed Web of Science ®Google Scholar
• Maser EA, Villela R, Silverber MS et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin. Gastroenterol. Hepatol.4(10), 1248–1254 (2006).
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long term efficacy of infliximab in Crohn’s disease. N. Eng. J. Med.348, 601–608 (2003).
   PubMed Web of Science ®Google Scholar
• Regueiro M, Siemanowski B, Kip KE et al. Infliximab dose intensification in Crohn’s disease. Inflamm. Bowel Dis.13(9), 1093–1099 (2007).
   PubMedGoogle Scholar
• Kaplan GG, Hur C, Korzenik J et al. Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment. Pharmacol. Ther.26(11–12), 1509–1520 (2007).
   PubMed Web of Science ®Google Scholar
• Robin X, Serre-Debeauvais F, Phelip JM et al. Drug interaction between infliximab and azathioprine in patients with Crohn’s disease. Aliment. Pharmacol. Ther.18, 917–925 (2003).
   PubMedGoogle Scholar
• Siemanowski B, Kip K, Pevy S et al. Adjustment in infliximab dose or dosing interval in Crohn’s disease: experience from the University of Pittsburgh. Gastroenterology130, A-142 (2006) (Abstract 924).
   Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin. Gastroenterol. Hepatol.2, 542–553 (2004).
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JW, Panaccione R et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn’s disease. Gastroenterology135(1), 294–295 (2008).
   Google Scholar
• Sandborn W, Rutgeerts, P, Reinishch W et al. Study of biologic and immunomodulator naive patients in Crohn’s disease. Am. J. Gastroenterol.103, 1117 (2008).
   Web of Science ®Google Scholar
• Van Assche G, Magdelaine-Beuzeline C, D’Hanes G et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled inflixmab maintenance: a randomized trial. Gastroenterology134, 1861–1868 (2008).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut56(9), 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• West R, Zelinkova Z, Wolbink G et al. Does immunogenicity play a role in adalimumab treatment or Crohn’s disease? J. Crohn’s Colitis2(1), 17 (2008) (DDW Abstract W1241).
   Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab for induction therapy for Crohn’s disease previously treated with infliximab: a randomized trial. Ann. Intern. Med.146(12), 829–838 (2007).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med.357(3), 239–250 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R et al. International Efficacy of Natalizumab as Active Crohn’s Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Eng. J. Med.353, 1912–1925 (2005).
   PubMed Web of Science ®Google Scholar
• Panaccione R, Colombel JF, Sandborn WJ et al. Adalimumab maintains long-term remission in moderately to severely active Crohn’s disease through 2 years. Gastroenterology134(4), A-134 (2008) (Abstract 920).
   Google Scholar
• Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm. Bowel Dis.8, 244–250 (2002).
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology105, 1716–1723 (1993).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest. Endosc.63, 433–442 (2006).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Hebuterne X. Endoscopic mucosal improvement in patients with active Crohn’s disease treated with certolizumab pegol: first result of the MUSIC clinical trial. Am. J. Gastroenterol.103, 13 (2008).
   Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum.54, 26–37 (2006).
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman Y, De Vries-Bouwstra J, Allaart C et al. Clinical and radiographic outcome of four different treatment strategies in patient with early rheumatoid arthritis (the BeSt study); a randomized controlled trial. Arthritis Rheum.52(11), 3381–3390 (2005).
   PubMed Web of Science ®Google Scholar
• Lemann M, Mary JY, Colombel JF et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology128, 1812–1818 (2005).
   PubMed Web of Science ®Google Scholar
• Lemann M, Mary JY, Duclos B et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastoenterology130, 1054–1061 (2006).
   PubMed Web of Science ®Google Scholar
• Costes L, Colombel JF, Mary JY et al. Long term follow-up of a cohort of steroid dependent Crohn’s disease patients included in a randomized trial evaluating short term infliximab combined with azathioprine. J. Crohn’s Colitis2(1), 8 (2008) (DDW Abstract 921).
   Google Scholar
• D’Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet371, 660–667 (2008).
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I et al. Predictors of Crohn’s disease. Gastroenterology130, 650–656 (2006).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT Registry. Clin. Gastroenterol. Hepatol.4, 621–630 (2006).
   PubMed Web of Science ®Google Scholar